Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review

Authors Suzanne A Ligthart, Eric P Moll van Charante, Willem A Van Gool, et al

Published Date August 2010 Volume 2010:6 Pages 775—785

DOI http://dx.doi.org/10.2147/VHRM.S7343

Published 17 August 2010

Suzanne A Ligthart1, Eric P Moll van Charante1, Willem A Van Gool2, Edo Richard2
1Department of General Practice, 2Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Background: Over the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
Objective: To systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline.
Selection criteria: RCTs studying the effect of treating hypertension, dyslipidemia, ­hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations.
Outcome measure: Cognitive decline or incident dementia.
Main results: In the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
Conclusion: The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Keywords: cardiovascular risk factors, cognitive decline, dementia, prevention

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Cardiac allograft immune activation: current perspectives

Chang D, Kobashigawa J

Transplant Research and Risk Management 2015, 7:13-22

Published Date: 18 December 2014

Ex vivo and in vivo evaluation of an ultrasonic device for precise dissection, coagulation, and transection

Bertke BD, Scoggins PJ, Welling AL, Widenhouse TV, Chen C, Kallakuri S, Cavanaugh JM, Clymer JW, Amaral JF

Open Access Surgery 2015, 8:1-7

Published Date: 18 December 2014

Renal interstitial fibrosis induced by high-dose mesoporous silica nanoparticles via the NF-κB signaling pathway

Chen X, Zhouhua W, Jie Z, Xinlu F, Jinqiang L, Yuwen Q, Zhiying H

International Journal of Nanomedicine 2015, 10:1-22

Published Date: 18 December 2014

Transmyocardial revascularization devices: technology update

Kindzelski BA, Zhou Y, Horvath KA

Medical Devices: Evidence and Research 2015, 8:11-19

Published Date: 18 December 2014

Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells

Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ

International Journal of Nanomedicine 2012, 7:4973-4982

Published Date: 14 September 2012

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia

Ascher-Svanum H, Brnabic AJM, Lawson AH, Kinon BJ, Stauffer VL, Feldman PD, Kelin K

Neuropsychiatric Disease and Treatment 2012, 8:113-118

Published Date: 15 March 2012

Network analysis of single nucleotide polymorphisms in asthma

Jutta Renkonen, Sakari Joenväärä, Ville Parviainen, et al

Journal of Asthma and Allergy 2010, 3:177-186

Published Date: 9 December 2010

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment

Curtis Triplitt, Eugenio Cersosimo, Ralph A DeFronzo

Vascular Health and Risk Management 2010, 6:671-690

Published Date: 5 August 2010

Adolescent mental health: Challenges with maternal noncompliance

Vicki A Nejtek, Sarah Hardy, Scott Winter

Neuropsychiatric Disease and Treatment 2010, 6:67-69

Published Date: 30 March 2010